Gilmore O’Neill
President, CEO & DirectorDr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as its Director. He had served as an Independent Director at Aptinyx Inc. since October 2021 until April 2023. He had been Independent Director at Unity Biotechnology, Inc. since December 2020 until June 27, 2025. Dr. O’Neill has vast experience in drug development and medical and regulatory affairs. He served as Chief Medical Officer of Sarepta Therapeutics, Inc. and served as its Executive Vice President of Research and Development from June 2018 to November 2021 and led its research, clinical development, medical affairs, pharmacovigilance and regulatory affairs functions. He joined Sarepta Therapeutics in June 2018. During this period, Dr. O’Neill oversaw global marketing approvals for Tecfidera, Zinbryta, Plegridy and Spinraza. Previously, Dr. O’Neill spent years at Biogen Inc. holding leadership roles in development programs for Alzheimer’s disease, movement disorders, neurology, multiple sclerosis, pain, neuromuscular disease, gene and cell therapy and rare diseases and overseeing multiple global marketing approvals. Dr. O’Neill served as the Senior Vice President, Late Stage Clinical Development of Biogen Inc. from November 2016 to June 2018. At Biogen, Dr. O’Neill also served as Senior Vice President, Drug Innovation Units from October 2015 to November 2016. From June 2014 to October 2015, Dr. O’Neill served as Vice President, MS Franchise & Head, Multiple Sclerosis R&D at Biogen. He joined Biogen Inc. in April 2003 including Vice President, Global Neurology Clinical Development, Vice President, Global Late Stage Clinical Development and Vice President, Experimental Neurology (Early Stage). He serves on the Board of the Massachusetts Biotechnology Council (MassBio). He has served as a neurology peer reviewer for medical literature and lectures in the United States and globally on advances in neurology and neurological research. He is a Member of the American Academy of Neurology and a board-certified neurologist (ABPN). From 1997 to 2015, Dr. O’Neill served as a clinical instructor in neurology at Harvard Medical School. Dr. O’Neill has extensive experience in the healthcare industry, operating in executive roles with large pharmaceutical and biotechnology companies, as well as in academic medicine as a neurologist. Dr. O’Neill is licensed to practice medicine in the state of Massachusetts. He is the recipient of numerous awards in science and medicine, including the Lefler Fellowship in the Department of Neurobiology at Harvard Medical School. Dr. O’Neill, a board-certified neurologist, received a Bachelor of Medicine degree at University College Dublin and a Master of Medical Sciences degree from Harvard University. He completed his residency training in neurology at Massachusetts General Hospital, where he also served as Chief Resident.
Positions
- Company NameEditas Medicine, Inc.Stock CodeEDITPositionPresident, CEO & Director
